IMAGE CREDITS: COREWIRE / AI ILLUSTRATION

Crusoe in talks for $3B at a valuation near $30B, per Bloomberg

AI data-center company Crusoe is reportedly in talks to raise about $3 billion at a valuation near $30 billion, roughly triple its last mark. The round, first reported by Bloomberg, has not closed.

The AI infrastructure boom keeps finding new capital. Crusoe, the AI data-center company, is in talks to raise about $3 billion in a round that could value it near $30 billion, roughly triple its previous valuation, Bloomberg first reported, citing people familiar with the matter. The round is still in discussion and has not closed, a distinction worth keeping.

A tripled valuation for a neo-cloud says the market believes compute scarcity outlasts the current cycle. It rhymes with the demand signals landing elsewhere in the technology economy this quarter, from Dell’s $51.3 billion AI server backlog to the subsidized-compute war the model providers are waging for startups.

The neo-cloud squeeze

Crusoe and its peers sit in a demanding position: hyperscalers above them with balance sheets, model providers beside them subsidizing usage, and power constraints beneath everyone. Raising at a step-up this large is a bet that specialized capacity, sited where energy is cheap, stays scarce enough to price well into 2027 and beyond.

What to watch

Watch whether the round closes at the reported size and price, which investors lead it, and the capacity commitments announced alongside. In this market, the press release after the raise usually names the real customer. Days later, the demand side answered: Amazon opened a $25 billion bond sale for AI infrastructure. The same pattern showed up again in SambaNova’s $1 billion round, where a single named customer, JPMorgan, did more to explain the valuation than the funding number itself.

Get the Signal

AI and business tech news, verified by a physician who reads the filings. One email a week, no noise.

Dr. Joseph Joshua

Dr. Joseph Joshua is the founder and editor of Corewire. A medical doctor by training, he brings the evidence-first discipline of clinical medicine to technology journalism: claims get checked against primary sources before they get published. He has produced technology and B2B content for companies across…

View Bio

Keep Reading